Hutchmed China hails lung cancer trial results published in Lancet
(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More
| Price | 219.00p on 06-02-2026 at 19:35:12 |
|---|---|
| Change | -4.00p -1.83% |
| Buy | 219.00p |
| Sell | 209.00p |
| Last Trade: | Sell 500.00 at 211.00p |
| Day's Volume: | 5,063 |
| Last Close: | 214.00p |
| Open: | 207.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 207.00p - 219.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.88b |
| VWAP: | 210.25044p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 500 | 211.00p | Ordinary |
16:28:58 - 06-Feb-26 |
| Buy* | 332 | 219.00p | Automatic Execution |
16:27:27 - 06-Feb-26 |
| Buy* | 121 | 218.00p | Automatic Execution |
16:17:31 - 06-Feb-26 |
| Sell* | 121 | 213.00p | Automatic Execution |
16:09:19 - 06-Feb-26 |
| Buy* | 90 | 218.00p | Automatic Execution |
16:09:19 - 06-Feb-26 |
| Unknown* | 0 | 218.00p | SI Trade |
14:17:52 - 06-Feb-26 |
| Sell* | 1,713 | 209.00p | Ordinary |
11:37:32 - 06-Feb-26 |
| Sell* | 2,000 | 209.00p | Ordinary |
10:55:31 - 06-Feb-26 |
| Unknown* | 37 | 207.00p | OTC Trade |
08:54:09 - 06-Feb-26 |
| Unknown* | 29 | 207.00p | OTC Trade |
08:54:09 - 06-Feb-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 6th Feb 2026 8:30 am | RNS | HUTCHMED to Announce 2025 Final Results |
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |